文献速递肺血管病与心包/心肌炎

硒蛋白P促进肺动脉高压发展并可能成为新治疗靶点

Selenoprotein P Promotes the Development of Pulmonary Arterial Hypertension: Possible Novel Therapeutic Target.
PubMed 文献 · Circulation · 2018-01-01

该研究通过微阵列分析发现PAH-PASMCs中硒蛋白P(SeP)表达上调32倍,并在患者血清和肺组织中验证其升高与不良预后相关。机制上SeP通过增加氧化应激和线粒体功能障碍促进PASMC增殖和抗凋亡,而高通量筛选发现白屈菜红碱可降低SeP表达并改善动物模型中的PH。

要点

  • SeP在PAH-PASMCs中表达上调32倍,血清SeP升高预测PH患者不良结局。
  • SeP通过氧化应激和线粒体功能障碍促进PASMC增殖和抗凋亡。
  • 白屈菜红碱可降低SeP表达并改善小鼠和大鼠的PH。

核心结论

  • SeP促进肺动脉高压的发展,可能作为新型生物标志物和治疗靶点。

研究设计与样本

  • 研究采用微阵列分析、体外实验(包括PAH患者肺和血清样本、培养的PAH-PASMCs、3336种低分子量化合物的高通量筛选)、五种基因修饰小鼠品系(包括PASMC特异性SeP敲除小鼠)和PH模型大鼠。

主要发现

  • 微阵列分析显示PAH-PASMCs中SeP较对照PASMCs增加32倍。
  • PAH患者肺动脉中膜增厚区域SeP免疫反应性增强,PH患者血清SeP水平较对照升高,高血清SeP预测不良结局。
  • SeP-/-小鼠暴露于慢性缺氧后右心室收缩压、右心室肥厚和肺动脉重塑较对照显著减轻;全身SeP过表达小鼠缺氧诱导的PH加重。
  • PASMC特异性SeP-/-小鼠缺氧诱导的PH较对照减轻,而肝特异性SeP敲除或过表达小鼠与对照无显著差异。
  • 机制实验表明SeP通过增加氧化应激和线粒体功能障碍促进PASMC增殖和抗凋亡,与缺氧诱导因子-1α激活和谷胱甘肽代谢失调相关。

临床怎么用

  • 血清SeP可能作为PH的诊断和预后生物标志物。
  • 靶向SeP(如白屈菜红碱)可能成为PAH的新型治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Excessive proliferation and apoptosis resistance of pulmonary artery smooth muscle cells (PASMCs) are key mechanisms of pulmonary arterial hypertension (PAH). Despite the multiple combination therapy, a considerable number of patients develop severe pulmonary hypertension (PH) because of the lack of diagnostic biomarker and antiproliferative therapies for PASMCs. METHODS: Microarray analyses were used to identify a novel therapeutic target for PAH. In vitro experiments, including lung and serum samples from patients with PAH, cultured PAH-PASMCs, and high-throughput screening of 3336 low-molecular-weight compounds, were used for mechanistic study and exploring a novel therapeutic agent. Five genetically modified mouse strains, including PASMC-specific selenoprotein P (SeP) knockout mice and PH model rats, were used to study the role of SeP and therapeutic capacity of the compounds for the development of PH in vivo. RESULTS: Microarray analysis revealed a 32-fold increase in SeP in PAH-PASMCs compared with control PASMCs. SeP is a widely expressed extracellular protein maintaining cellular metabolism. Immunoreactivity of SeP was enhanced in the thickened media of pulmonary arteries in PAH. Serum SeP levels were also elevated in patients with PH compared with controls, and high serum SeP predicted poor outcome. SeP-knockout mice ( SeP-/-) exposed to chronic hypoxia showed significantly reduced right ventricular systolic pressure, right ventricular hypertrophy, and pulmonary artery remodeling compared with controls. In contrast, systemic SeP-overexpressing mice showed exacerbation of hypoxia-induced PH. Furthermore, PASMC-specific SeP-/- mice showed reduced hypoxia-induced PH compared with controls, whereas neither liver-specific SeP knockout nor liver-specific SeP-overexpressing mice showed significant differences with controls. Altogether, protein levels of SeP in the lungs were associated with the development of PH. Mechanistic experiments demonstrated that SeP promotes PASMC proliferation and resistance to apoptosis through increased oxidative stress and mitochondrial dysfunction, which were associated with activated hypoxia-inducible factor-1α and dysregulated glutathione metabolism. It is important to note that the high-throughput screening of 3336 compounds identified that sanguinarine, a plant alkaloid with antiproliferative effects, reduced SeP expression and proliferation in PASMCs and ameliorated PH in mice and rats. CONCLUSIONS: These results indicate that SeP promotes the development of PH, suggesting that it is a novel biomarker and therapeutic target of the disorder.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Kikuchi N, Satoh K, Kurosawa R, et al. Selenoprotein P Promotes the Development of Pulmonary Arterial Hypertension: Possible Novel Therapeutic Target. Circulation. 2018. PMID: 29636330. doi:10.1161/CIRCULATIONAHA.117.033113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。